文献速递角膜与眼表疾病眼外伤

角膜移植随访研究II(CTFS II):一项探讨HLA II类配型对角膜移植排斥影响的前瞻性临床试验:供受体基线特征

Corneal transplant follow-up study II (CTFS II): a prospective clinical trial to determine the influence of HLA class II matching on corneal transplant rejection: baseline donor and recipient characteristics.
PubMed 文献 · Br J Ophthalmol · 2018-03-22

该前瞻性纵向临床试验旨在确定HLA II类配型对高危全层角膜移植排斥的影响,主要结局为首次临床判定排斥时间。共纳入1998年9月3日至2011年6月2日间的1133例移植(980例患者),17%移植为0个HLA-DR错配,最常见适应证为大泡性角膜病变(27%),54%为再次移植。招募已关闭,1077/1133移植符合全部研究标准,随访已完成,最终分析已开始。

要点

  • 共纳入1133例移植(980例患者),1077/1133移植符合全部研究标准。
  • 17%移植为0个HLA-DR错配,最常见适应证为大泡性角膜病变(27%),54%为再次移植。
  • 配型移植的中位等待时间为3个月,供受体特征在研究组间分布均匀。

核心结论

  • CTFS II招募已关闭,1077/1133移植符合全部研究标准,随访已完成,最终数据分析已开始。

研究设计与样本

  • 前瞻性纵向临床试验(ISRCTN25094892),主要结局为首次临床判定排斥时间。
  • 采用DNA技术进行组织分型,通过队列最小化将角膜分配给≤2个HLA I类抗原错配的患者,以实现0、1或2个HLA II类(HLA-DR)抗原错配。
  • 计划在术后6个月及此后每年手术周年随访,共5年。
  • 功效计算估计需856例移植,以在5%显著性水平、80%功效下检测HLA II类配型与错配移植间1年排斥概率0.1的差异。

主要发现

  • 1998年9月3日至2011年6月2日期间共纳入1133例移植(980例患者)。
  • 17%的移植为0个HLA-DR错配。
  • 最常见适应证为大泡性角膜病变,占27%的移植,54%的移植为再次移植。
  • 配型移植的中位等待时间为3个月。
  • 供受体特征在研究组间分布均匀。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe a study to determine the influence of HLA class II matching on allograft rejection of high-risk, full-thickness corneal transplants. METHODS: A prospective, longitudinal, clinical trial (ISRCTN25094892) with a primary outcome measure of time to first clinically determined rejection episode. Tissue typing used DNA-based techniques. Corneas were allocated to patients with ≤2 human leucocyte antigen (HLA) class I antigen mismatches by cohort minimisation to achieve 0, 1 or 2 HLA class II (HLA-DR) antigen mismatches. Transplants were to be followed up at 6 months and then annually on the anniversary of surgery for 5 years. Power calculations estimated a sample size of 856 transplants to detect a 0.1 difference in probability of rejection at 1 year between HLA class II matched and mismatched transplants at the 5% level of significance with 80% power. RESULTS: To allow for loss to follow-up, 1133 transplants in 980 patients were accrued to the study between 3 September 1998 and 2 June 2011. 17% of transplants had 0 HLA-DR mismatches. The most frequent indication was bullous keratopathy, accounting for 27% of transplants and 54% of the transplants were regrafts. Median waiting time for a matched graft was 3 months. Donor and recipient characteristics were distributed evenly across the study groups. CONCLUSION: Recruitment to the CFS II has closed with 1077/1133 transplants meeting all the study criteria. Follow-up has been completed and final analysis of the data has started. TRIAL REGISTRATION NUMBER: ISRCTN25094892 andUKCRNID9871, Pre-results.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Armitage WJ, Winton HL, Jones MNA, et al. Corneal transplant follow-up study II (CTFS II): a prospective clinical trial to determine the influence of HLA class II matching on corneal transplant rejection: baseline donor and recipient characteristics. Br J Ophthalmol. 2018. PMID: 29567793. doi:10.1136/bjophthalmol-2017-311342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。